Intravenous immunoglobulins in multiple sclerosis: Studies and mechanisms - An update;Intravenöse immunglobuline bei multipler sklerose: Studien und wirkmechanismen - Ein update

Nervenarzt

Volumn 73, Issue 2, 2002, Pages 119-124

  Stangel, M ^a   Hartung, H P ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Immunomodulation; Intravenous immunoglobulins; Multiple sclerosis; Remyelination; Treatment

Indexed keywords

IMMUNOGLOBULIN;

CELL FUNCTION; DRUG EFFECT; HUMAN; HYPOTHESIS; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MICROENVIRONMENT; MICROGLIA; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; RELAPSE; REMYELINIZATION; REVIEW; ANIMAL; CLINICAL TRIAL; DISEASE MODEL; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MYELIN SHEATH; PASSIVE IMMUNIZATION; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; INFUSIONS, INTRAVENOUS; MICE; MULTIPLE SCLEROSIS; MYELIN SHEATH; TREATMENT OUTCOME;

EID: 0036483368     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-001-1235-6     Document Type: Review

References (44)

1. Achiron A, Gabbay U, Gilad R et al. (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398-402
2. Achiron A, Pras E, Gilad R, Ziv I et al. (1992) Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 49:1233-1236
3. Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R (1996) Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 243:25-28
4. Andersson J, Skansén-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 104 [Suppl 1]:10-20
5. Asakura K, Miller DJ, Murray K, Bansal R, Pfeiffer SE, Rodriguez M (1996) Monoclonal autoantibody SCH94.03, which promotes CNS remyelination, recognizes an antigen on the surface of oligodendrocytes. J Neurosci Res 43:273-281
6. Asakura K, Miller DJ, Pease LR, Rodriguez M (1998) Targeting of IgMk antibodies to oligo-dendrocytes promotes CNS remyelination. J Neurosci 18:7700-7708
7. Carroll WM, Jennings AR, Ironside LJ (1998) Identification of the adult resting progenitor cell by autoradiographic tracking of oligo-dendrocyte precursors in experimental CNS demyelination. Brain 121:293-302
8. Compston A, Zajicek J, Sussman J et al. (1997) Glial lineages and myelination in the central nervous system. J Anat 190:161-200
9. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T, the Pregnancy in Multiple Sclerosis Group (1998) Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 339:285-291
10. Copelman CA, Cuzner ML, Groome N, Diemel LT (2000) Temporal analysis of growth factor mRNA expression in myelinating rat brain aggregate cultures: increments in CNTF, FGF-2, IGF-I, and PDGF-AA mRNA are induced by antibody-mediated demyelination. Glia 30:342-351
11. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, for the Austrian Immunoglobulin in Multiple Sclerosis Study Group (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 349:589-593
12. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, for the Austrian Immunoglobulin in Multiple Sclerosis Study Group (1997) Treatmet effects of monthly intravenous immunoglobulin on patients with relapsing-remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS study. Mult Scler 3: 137-141
13. Franklin RJM, Hinks GL (1999) Understanding CNS remyelination: clues from developmental and regeneration biology. J Neurosci Res 58:207-213
14. Haas J (2000) High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler 6 [Suppl 2]:18-20
15. Imbach P, Barandun S, d'Apuzzo V et al. (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228-1231
16. Kalanie H, Tabatabai SS (1998) Combined immunoglobulin and azathioprine in multiple sclerosis. Eur Neurol 39:178-181
17. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 47:707-717
18. Mauch E (2000) IVIG bei mitoxantronresistenter Multipler Sklerose. In: Kiehl MG, Naß WP, Volk H-D (Hrsg) Immunmodulation mit Immunglobulinen bei Autoimmunerkrankungen und Infektionen. Thieme, Stuttgart, pp 80-82
19. Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD (1996) Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 104 [Suppl 1]:3-9
20. Multiple Sklerose Therapie Konsensus Gruppe (1999) Immunmodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt 70:371-386
21. Multiple Sklerose Therapie Konsensus Gruppe (2001) Immunmodulatorische Stupentherapie der multiplen Sklerose. 1. Ergänzung: Dezember 2000. Nervenarzt 72:150-157
22. Noseworthy JH, O'Brien PC, Petterson TM et al. (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56:1514-1522
23. Noseworthy JH, O'Brien PC, Weinshenker BG et al. (2000) IV immunoglobulin does not reverse established weakness in MS. A double-blind, placebo-controlled trial. Neurology 55:1135-1143
24. Noseworthy JH, Rodriguez M, An K-N et al. (1994) IVIg treatment in multiple sclerosis: pilot study results and design of a placebo-controlled, double-blind clinical trial. Ann Neurol 36:325-325
25. Orvieto R, Achiron R, Rotstein Z, Noy S, Bar-Hava I, Achiron A (1999) Pregnancy and multiple sclerosis: a 2-year experience. Eur J Obstet Gynecol Reprod Biol 82:191-194
26. Pavelko KD, van Engelen BGM, Rodriguez M (1998) Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. J Neurosci 18:2498-2505
27. Rodriguez M, Lennon VA (1990) Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 27:12-17
28. Rodriguez M, Miller DJ, Lennon VA (1996) Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 46:538-545
29. Rothfelder U, Neu I, Pelka R (1982) Therapie der Multiplen Sklerose mit Immunglobulin G. Münch Med Wochenschr 124:48-54
30. Schuller E, Govaerts A (1983) First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 22:205-212
31. Sorensen PS, Wanscher B, Jensen CV et al. (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273-1281
32. Soukop W, Tschabitscher H (1986) Gammaglobulintherapie be Multipler Sklerose (MS). Wien Med Wochenschr 136:477-480
33. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S (2000) A placebo-controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68:89-92
34. Stangel M, Compston A (2001) Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. J Neuroimmunol 112:63-71
35. Stangel M, Compston A, Scolding NJ (1999) Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes. J Neuroimmunol 96:228-233
36. Stangel M, Compston A, Scolding NJ (2000) Oligodendroglia are protected from antibody mediated complement injury by normal immunoglobulins ("IVIg"). J Neuroimmunol 103:195-201
37. Stangel M, Joly E, Scolding NJ, Compston DAS (2000) Normal polyclonal immunoglobulins ("IVIg") inhibit microglial phagocytosis in vitro. J Neuroimmunol 106:137-144
38. Stangel M, Toyka KV, Gold R (1999) Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 56:661-663
39. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H (1998) Multiple sclerosis: In situ evidence for antibody-and complement-mediated demyelination. Ann Neurol 43:465-471
40. Teksam M, Tali T, Kocer B, Isik S (2000) Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report. Neuroradiology 42:885-889
41. Tenser RB, Hay KA, Aberg JA (1993) Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets. Arch Neurol 50:417-420
42. van Engelen BGM, Hommes OR, Pinckers A, Cruysberg JRM, Barkhof F, Rodriguez M (1992) Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 32:834-835
43. Warrington AE, Asakura K, Bieber AJ et al. (2000) Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci 97:6820-6825
44. Woodruff RH, Franklin RJM (1997) Growth factors and remyelination. Histol Histopathol 12:459-466